Wellington Management Group
RPRX icon

Wellington Management Group’s Royalty Pharma RPRX Stock Holding History

Wellington Management Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$398K Sell
7,105
-26
-0.4% -$1.35K ﹤0.01% 1851
2026
Q1 		$342K Buy
7,131
+258
+4% +$11.3K ﹤0.01% 1808
2025
Q4 		$266K Hold
6,873
– – ﹤0.01% 1865
2025
Q3 		$242K Buy
+6,873
New +$249K ﹤0.01% 1935
2025
Q1 		– Sell
-18,539
Closed -$473K – 2035
2024
Q4 		$473K Buy
18,539
+733
+4% +$19.4K ﹤0.01% 1840
2024
Q3 		$504K Sell
17,806
-39,598
-69% -$1.1M ﹤0.01% 1816
2024
Q2 		$1.51M Buy
57,404
+743
+1% +$20.6K ﹤0.01% 1577
2024
Q1 		$1.72M Buy
56,661
+17,676
+45% +$521K ﹤0.01% 1550
2023
Q4 		$1.1M Sell
38,985
-51,461
-57% -$1.41M ﹤0.01% 1609
2023
Q3 		$2.45M Sell
90,446
-748
-0.8% -$22.2K ﹤0.01% 1433
2023
Q2 		$2.8M Buy
91,194
+38,944
+75% +$1.32M ﹤0.01% 1408
2023
Q1 		$1.88M Sell
52,250
-3,338,671
-98% -$124M ﹤0.01% 1529
2022
Q4 		$134M Sell
3,390,921
-560,196
-14% -$23.4M 0.03% 465
2022
Q3 		$159M Buy
3,951,117
+586,514
+17% +$25.1M 0.03% 415
2022
Q2 		$141M Buy
3,364,603
+264,773
+9% +$10.9M 0.03% 460
2022
Q1 		$121M Sell
3,099,830
-5,478
-0.2% -$215K 0.02% 547
2021
Q4 		$124M Sell
3,105,308
-23,097
-0.7% -$897K 0.02% 578
2021
Q3 		$113M Sell
3,128,405
-1,175,121
-27% -$45.7M 0.02% 588
2021
Q2 		$176M Sell
4,303,526
-589,607
-12% -$25.1M 0.03% 471
2021
Q1 		$213M Sell
4,893,133
-975,796
-17% -$46.3M 0.04% 411
2020
Q4 		$294M Buy
5,868,929
+168,816
+3% +$7.16M 0.05% 321
2020
Q3 		$240M Buy
5,700,113
+94,582
+2% +$4.06M 0.05% 322
2020
Q2 		$272M Buy
+5,605,531
New +$277M 0.06% 273

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group's RPRX Position: Q2 2026 in Review

Wellington Management Group reduced its Royalty Pharma (RPRX) stake by 0.36% in Q2 2026, selling an estimated $1.35K and leaving 7,105 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #1851.

Wellington Management Group first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $294M in Q4 2020. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Wellington Management Group held 7,105 shares of Royalty Pharma worth $398K as of Q2 2026.
  • Wellington Management Group sold 26 Royalty Pharma shares in Q2 2026, an estimated $1.35K.
  • Royalty Pharma made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1851 holding.
  • Wellington Management Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
  • Wellington Management Group's Royalty Pharma position peaked at $294M in Q4 2020.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.